青藤碱衍生物调变多发性骨髓瘤细胞趋化因子受体的实验研究

居身傲男; 王莹莹; 唐勇; 姚一芸; 吴英理; 朱琦

doi:10.19401/j.cnki.1007-3639.2023.06.006

您当前的位置：

首页 >

文章列表页 >

青藤碱衍生物调变多发性骨髓瘤细胞趋化因子受体的实验研究

论著 | 更新时间：2025-12-31

- 青藤碱衍生物调变多发性骨髓瘤细胞趋化因子受体的实验研究
- Experimental study on sinomenine derivative modulating chemokine receptor in multiple myeloma cells
- 中国癌症杂志 2023年33卷第6期页码：589-596
- 作者机构：
  
  1. 上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科，上海 200011
  2. 上海交通大学医学院病理生理学系，细胞分化与凋亡教育部重点实验室，上海 200025
  3. 上海交通大学医学院附属第九人民医院黄浦分院血液肿瘤内科，上海 200011
- 作者简介：
  
  [ "居身傲男（ORCID: 0000-0002-3675-5099），上海交通大学医学院内科学研究生。" ]
  朱琦（ORCID: 0000-0002-7128-806X），主任医师，E-mail: zhuqi70@hotmail.com。
- 基金信息：
  
  国家自然科学基金(81870156)
- DOI：10.19401/j.cnki.1007-3639.2023.06.006
  中图分类号： R733.3
- 收稿：2022-12-22，
  
  修回：2023-05-04，
  
  纸质出版：2023-06-30
- 稿件说明：
移动端阅览
居身傲男, 王莹莹, 唐勇, 等. 青藤碱衍生物调变多发性骨髓瘤细胞趋化因子受体的实验研究[J]. 中国癌症杂志, 2023,33(6):589-596.

Shenaonan JU, Yingying WANG, Yong TANG, et al. Experimental study on sinomenine derivative modulating chemokine receptor in multiple myeloma cells[J]. China Oncology, 2023, 33(6): 589-596.
居身傲男, 王莹莹, 唐勇, 等. 青藤碱衍生物调变多发性骨髓瘤细胞趋化因子受体的实验研究[J]. 中国癌症杂志, 2023,33(6):589-596. DOI： 10.19401/j.cnki.1007-3639.2023.06.006.

Shenaonan JU, Yingying WANG, Yong TANG, et al. Experimental study on sinomenine derivative modulating chemokine receptor in multiple myeloma cells[J]. China Oncology, 2023, 33(6): 589-596. DOI： 10.19401/j.cnki.1007-3639.2023.06.006.

摘要

背景与目的：

多发性骨髓瘤（multiple myeloma，MM）细胞表面CXC族趋化因子受体（CXC motif chemokine receptor，CXCR）与骨髓微环境内趋化因子相互作用参与MM细胞生存、增殖和髓外侵袭。青藤碱衍生物YL064通过靶向MM细胞内信号转导通路分子发挥其生物学效应。本研究探究青藤碱衍生物YL064对MM细胞表面CXCR3的调变作用及其生物学效应。

方法：

以MM细胞系H929和MM1.S细胞为模型，利用慢病毒载体构建过表达CXCR3的H929-OE和MM1.S-OE细胞，采用克隆形成和体外迁移实验检测并比较H929、H929-OE、MM1.S和MM1.S-OE细胞克隆形成和迁移率；采用流式细胞术检测YL064处理后H929、H929-OE、MM1.S和MM1.S-OE细胞凋亡率；进一步以不同浓度YL064处理H929和MM1.S细胞，采用实时荧光定量聚合酶链反应（real-time fluorescence quantitative polymerase chain reaction，RTFQ-PCR）和蛋白质印迹法（Western blot）检测细胞内

CXCR

3基因转录和蛋白水平及其下游信号转导通路关键分子细胞外调节蛋白激酶（extracellular regulated protein kinase，ERK）和p-蛋白激酶B（p-protein kinase B，p-AKT）蛋白水平的改变。

结果：

CXCR3过表达H929-OE和MM1.S-OE细胞克隆形成率分别为81.33%±5.79%和73.00%±4.90%，显著高于H929的58.33%±3.30%和MM1.S细胞的41.00%±3.14%；H929-OE和MM1.S-OE细胞迁移率分别为7.90%±0.81%和23.00%±1.63%，显著高于H929的4.63%±0.37%和MM1.S细胞的14.63%±1.04%；经YL064处理后，H929-OE和MM1.S-OE细胞凋亡率分别为29.80%±0.30%和14.2%±0.26%，显著低于H929的33.40%±0.25%和MM1.S细胞的21.60%±0.21%；上述结果比较差异有统计学意义（

均

0.05）。进一步研究发现YL064能够降低H929和MM1.S细胞克隆形成率和迁移率，同时抑制细胞内

CXCR

3基因转录并下调CXCR3、ERK和AKT蛋白表

达。

结论：

CXCR3可以促进MM细胞增殖和迁移，青藤碱衍生物YL064能够下调MM细胞内CXCR3表达并抑制其下游信号转导通路进而干扰其增殖和迁移并诱导凋亡。

Abstract

Background and purpose:

The interaction of CXC motif chemokine receptor (CXCR) on the cell surface of multiple myeloma (MM) with chemokines in the bone marrow microenvironment is involved in proliferation

survival and extramedullary invasion of MM cells. Sinomenine derivative YL064 exerts its biological effects by targeting intracellular signaling regulators in MM cells. This study aimed to explore possible modulating and biological effects of sinomenine derivative YL064 on CXCR3 in MM cells.

Methods:

The MM cell lines H929 and MM1.S were used as

in vitro

models. H929-OE and MM1.S-OE cells with stable overexpression of CXCR3 were constructed with lentivirus vector. The effects of CXCR3 on clonal formation and migration of MM cells were detected by clone spot formation and transwell migration assay. Meanwhile

flow cytometry was used to analyze apoptotic rates of H929

H929-OE

MM1.S and MM1.S-OE cells treated with different concentrations of YL064. Furthermore

real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR) and Western blot assay were applied to detect expression levels of CXCR3 and its downstream signal regulators extracellular regulated protein kinase (ERK) and p-protein kinase B (p-AKT) in H929 and MM1.S cells before and after the treatment with YL064.

Results:

The clonal formation rates of H929-OE and MM1.S-OE cells with CXCR3 overexpression reached to 81.33%±5.79% and 73.00%±4.90%

which were significantly higher compared with H929 (58.33%±3.30%) and MM1.S cells (41.00%±3.14%). The migration proportion of H929-OE and MM1.S-OE cells were 7.90%±0.81% and 23.00%±1.63%

which were significantly higher compared with H929 (4.63%±0.37%) and MM1.S cells (14.63%±1.04%). After treatment with YL064

the apoptotic rates of H929-OE and MM1.S-OE cells were 29.80%

±0.30% and 14.20%±0.26%

which were lower than those of H929 (33.40%±0.25%) and MM1.S cells (21.60%±0.21%). It was also shown that YL064 could reduce clonal formation and migration

inhibit CXCR3 gene transcription and downregulate expressions of CXCR3

ERK and AKT in H929 and MM1.S cells.

Conclusions:

CXCR3 might promote proliferation and invasion of MM cells. Sinomenine derivative YL064 could downregulate expressions of CXCR3 and its downstream signal regulators in MM cells

reduce abilities of clonal formation and migration

and induce apoptosis.

关键词

Keywords

references

VAN DE DONK N W C J , PAWLYN C, YONG K L. Multiple myeloma [J ] . Lancet , 2021 , 397 ( 10272 ): 410 - 427 . DOI: 10.1016/S0140-6736(21)00135-5 http://doi.org/10.1016/S0140-6736(21)00135-5

KOH H M , HYUN C L , JANG B G , et al. CXCR3 expression as a prognostic factor in gastric cancer: a meta-analysis [J ] . Transl Cancer Res , 2021 , 10 ( 3 ): 1449 - 1456 . DOI: 10.21037/tcr-20-2862 http://doi.org/10.21037/tcr-20-2862

MA B , KHAZALI A , SHAO H S , et al. Expression of E-cadherin and specific CXCR3 isoforms impact each other in prostate cancer [J ] . Cell Commun Signal , 2019 , 17 ( 1 ): 164 . DOI: 10.1186/s12964-019-0489-1 http://doi.org/10.1186/s12964-019-0489-1

GUDOWSKA-SAWCZUK M , KUDELSKI J , MROCZKO B . The role of chemokine receptor CXCR3 and its ligands in renal cell carcinoma [J ] . Int J Mol Sci , 2020 , 21 ( 22 ): 8582 . DOI: 10.3390/ijms21228582 http://doi.org/10.3390/ijms21228582 https://www.mdpi.com/1422-0067/21/22/8582 https://www.mdpi.com/1422-0067/21/22/8582

CHEN X N , HE H , XIAO Y , et al. CXCL10 produced by HPV-positive cervical cancer cells stimulates exosomal PDL1 expression by fibroblasts via CXCR3 and JAK-STAT pathways [J ] . Front Oncol , 2021 , 11 : 629350 . DOI: 10.3389/fonc.2021.629350 http://doi.org/10.3389/fonc.2021.629350 https://www.frontiersin.org/articles/10.3389/fonc.2021.629350/full https://www.frontiersin.org/articles/10.3389/fonc.2021.629350/full

VANDE BROEK I , VANDERKERKEN K , VAN CAMP B , et al. Extravasation and homing mechanisms in multiple myeloma [J ] . Clin Exp Metastasis , 2008 , 25 ( 4 ): 325 - 334 . DOI: 10.1007/s10585-007-9108-4 http://doi.org/10.1007/s10585-007-9108-4 http://link.springer.com/10.1007/s10585-007-9108-4 http://link.springer.com/10.1007/s10585-007-9108-4

ULLAH T R . The role of CXCR4 in multiple myeloma: cells’ journey from bone marrow to beyond [J ] . J Bone Oncol , 2019 , 17 : 100253 . DOI: 10.1016/j.jbo.2019.100253 http://doi.org/10.1016/j.jbo.2019.100253 https://linkinghub.elsevier.com/retrieve/pii/S2212137419301368 https://linkinghub.elsevier.com/retrieve/pii/S2212137419301368

WANG Y Y , WU L L , CAI H Y , et al. YL064 directly inhibits STAT3 activity to induce apoptosis of multiple myeloma cells [J ] . Cell Death Discov , 2018 , 4 : 44 . DOI: 10.1038/s41420-018-0108-8 http://doi.org/10.1038/s41420-018-0108-8

SOLIMANDO A G , MALERBA E , LEONE P , et al. Drug resistance in multiple myeloma: soldiers and weapons in the bone marrow niche [J ] . Front Oncol , 2022 , 12 : 973836 . DOI: 10.3389/fonc.2022.973836 http://doi.org/10.3389/fonc.2022.973836 https://www.frontiersin.org/articles/10.3389/fonc.2022.973836/full https://www.frontiersin.org/articles/10.3389/fonc.2022.973836/full

MAISO P , MOGOLLÓN P , OCIO E M , et al. Bone marrow mesenchymal stromal cells in multiple myeloma: their role as active contributors to myeloma progression [J ] . Cancers (Basel) , 2021 , 13 ( 11 ): 2542 . DOI: 10.3390/cancers13112542 http://doi.org/10.3390/cancers13112542 https://www.mdpi.com/2072-6694/13/11/2542 https://www.mdpi.com/2072-6694/13/11/2542

PELLEGRINO A , ANTONACI F , RUSSO F , et al. CXCR3-binding chemokines in multiple myeloma [J ] . Cancer Lett , 2004 , 207 ( 2 ): 221 - 227 . DOI: 10.1016/j.canlet.2003.10.036 http://doi.org/10.1016/j.canlet.2003.10.036

GIULIANI N , BONOMINI S , ROMAGNANI P , et al. CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival [J ] . Haematologica , 2006 , 91 ( 11 ): 1489 - 1497 .

LUDWIG H , WEISEL K , PETRUCCI M T , et al. Olaptesed pegol, an anti-CXCL12/SDF-1 spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a phase Ⅱa study [J ] . Leukemia , 2017 , 31 ( 4 ): 997 - 1000 . DOI: 10.1038/leu.2017.5 http://doi.org/10.1038/leu.2017.5

WANG Y Y , WU L L , CAI H Y , et al. Sinomenine derivative YL064: a novel STAT3 inhibitor with promising anti-myeloma activity [J ] . Cell Death Dis , 2018 , 9 : 1093 . DOI: 10.1038/s41419-018-1147-z http://doi.org/10.1038/s41419-018-1147-z

REN Z M , LANTERMANS H , KUIL A , et al. Correction to: the CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma [J ] . J Hematol Oncol , 2021 , 14 ( 1 ): 29 . DOI: 10.1186/s13045-021-01038-w http://doi.org/10.1186/s13045-021-01038-w

浏览量

2192

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

孟鲁司特钠靶向USP2诱导骨髓瘤细胞凋亡的实验研究

三氧化二砷联合环腺苷酸拟似物诱导骨髓瘤细胞凋亡的实验研究

多发性骨髓瘤的诊断进展与分期

间断口服伐昔洛韦预防多发性骨髓瘤患者应用硼替佐米致带状疱疹的临床观察